Saving sight through an innovative vision
NuVision was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma.
Omnigen™ is a unique ‘off the shelf’, transportable biological matrix that can be used as an effective ophthalmic wound dressing and to treat ocular surface indications.
A message from our CEO
With a strong, experienced team, supported by a history of innovative research, we have the products that have the potential to revolutionise ophthalmic wound care worldwide. Having over 15 year’s expertise in ocular regenerative medicine, and personally evolving Omnigen™ from concept to commercialisation, I believe NuVision has endless potential for growth.Andrew Hopkinson
The Tereo™ process is a patented and proprietary manufacturing procedure which renders fresh amniotic membrane, and thus associated wound healing promoting characteristics, as a dry and stable biological matrix that can be distributed and stored at room temperature on the shelf of any medical facility. Tereo processed amniotic membrane (Omnigen) can be used directly from the packaging dry with ease allowing rapid in vivo rehydration from eye moisture.
Connect with Us
NuVision Biotherapies has now been granted a license for export of Omnigen by the Human Tissue Authority #savingsightworldwide
- Monday Oct 24 - 3:33pm